1-hydroxy-cis,cis,cis-6,9,12-octadecatriene

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-hydroxy-cis,cis,cis-6,9,12-octadecatriene
• 英文别名: z,z,z,octadeca-6,9,12-trienol；gamma-linolenyl alcohol；octadeca-6,9,12-trienol；z,z,z,-octadeca-6,9,12-trienol；6,9,12-Octadecatrien-1-ol；(6E,9E,12E)-octadeca-6,9,12-trien-1-ol
• 化学式: C₁₈H₃₂O
• 分子量: 264.451
• InChiKey: WFYSUQMCIPGKKK-YHTMAJSVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  19
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-hydroxy-cis,cis,cis-6,9,12-octadecatriene 生成 γ-linolenyl mesylate
  参考文献：
  名称：

  J. Am. Oil Chem. Soc. 2009, 86, 77-82

  摘要：

  DOI：
• 作为产物：
  描述：

  γ-亚麻酸 生成 1-hydroxy-cis,cis,cis-6,9,12-octadecatriene
  参考文献：
  名称：

  J. Am. Oil Chem. Soc. 2009, 86, 77-82

  摘要：

  DOI：

文献信息

• 8,12-Dialkyl-PGE, and PGF.sub.1.sub..alpha.
  申请人：The Upjohn Company

  公开号：US03953499A1

  公开（公告）日：1976-04-27

  Prostaglandins E.sub.1 -type and F.sub.1 -type compounds of the formula ##EQU1## wherein R is hydrogen or a hydrocarbyl group containing from 1 to 12 carbon atoms, inclusive, wherein W is ##EQU2## or O =, wherein R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13, and R.sub.14 are hydrogen or alkyl of 1 to 4 carbon atoms, inclusive, provided (1) that at least one of R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13, and R.sub.14 is alkyl (2) that when R.sub.13 is alkyl, at least one of R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, and R.sub.14 is alkyl, and (3) that when R.sub.7 is alkyl or thwn R.sub.7 and R.sub.8 are alkyl, at least one of R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13, and R.sub.14 is alkyl; and the enantiomers and racemic mixtures thereof. These are useful for the same pharmacological purposes as the unsubstituted prostaglandins.

  前列腺素E.sub.1-型和F.sub.1-型化合物的化学式为##EQU1##其中R为氢或含有1至12个碳原子的烃基，其中W为##EQU2##或O=，其中R.sub.7、R.sub.8、R.sub.9、R.sub.10、R.sub.11、R.sub.12、R.sub.13和R.sub.14为氢或1至4个碳原子的烷基，满足以下条件：(1)至少有一个R.sub.7、R.sub.8、R.sub.9、R.sub.10、R.sub.11、R.sub.12、R.sub.13和R.sub.14为烷基；(2)当R.sub.13为烷基时，至少有一个R.sub.7、R.sub.8、R.sub.9、R.sub.10、R.sub.11、R.sub.12和R.sub.14为烷基；(3)当R.sub.7为烷基或R.sub.7和R.sub.8为烷基时，至少有一个R.sub.9、R.sub.10、R.sub.11、R.sub.12、R.sub.13和R.sub.14为烷基；以及它们的对映体和消旋混合物。这些化合物可用于与未取代前列腺素相同的药理目的。
• Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
  申请人：Shinitzky Meir

  公开号：US20060173053A1

  公开（公告）日：2006-08-03

  Basic esters of fatty alcohols of the general formula: R1-O—CO-A or pharmaceutically acceptable salts thereof, wherein R1 is C 12 -C 24 alkyl or C 10 -C 24 alkenyl, and A is a residue containing at least one acyclic or cyclic amino group and/or at least one heteroaromatic ring containing a tertiary or quaternary nitrogen atom, are anti-inflammatory and immunomodulatory agents, useful in the treatment of immunologically-mediated inflammation, as adjuvants for antigens involved in both cellular and humoral responses.

  一般式为R1-O-CO-A的脂肪醇基本酯或其药学上可接受的盐，其中R1为C12-C24烷基或C10-C24烯基，A为含有至少一个无环或环状氨基团和/或至少一个含有三级或四级氮原子的杂环芳香环的残基，具有抗炎和免疫调节作用，可用于治疗免疫介导的炎症，并作为细胞和体液反应中涉及的抗原的佐剂。
• Triglycerides
  申请人：SCOTIA HOLDINGS PLC

  公开号：EP0611569A2

  公开（公告）日：1994-08-24

  A triglyceride for use in therapy or as a nutritional supplement, or a composition containing a triglyceride, wherein the triglyceride comprises a fatty acid selected from gamma-linolenic acid and the n-6 EPAs naturally derived therefrom and stearidonic acid and the n-3 EFAs naturally derived therefrom, forming a triple ester with glycerol or alternatively forming a double ester in which the other esterifying acide is a single residue of linoleic acid, with the proviso that the di-gammalinolenoyl-mono-linoleoyl glyceride if selected is used as a preparation containing more than 20% by weight thereof.

  一种用于治疗或作为营养补充剂的甘油三酯，或一种含有甘油三酯的组合物，其中甘油三酯包含一种选自γ-亚麻酸及其天然衍生的n-6 EPA和硬脂二十二酸及其天然衍生的n-3 EFA的脂肪酸、与甘油形成三重酯，或形成双重酯，其中另一个酯化酸是亚油酸的单一残基，但如果选择了二甘氨酰-单亚油酰甘油酯，则将其用作制剂，按重量计，其含量超过 20%。
• Derivatives of essential fatty acids and nonsteroidal antiinflammatory drugs
  申请人：SCOTIA HOLDINGS PLC

  公开号：EP0675103A2

  公开（公告）日：1995-10-04

  An NSAID in the form of a compound with an essential fatty acid or essential fatty acid alcohol, particularly an NSAID as listed in categories 1 to 9 herein. Further, a method of preparation of a medicament for the treatment including prophylatic treatment of rheumatoid arthritis, osteoarthritis and related disorders; dysmenorrhoea; dementias, including Alzheimer's disease; or any other inflammatory or other conditions specified herein, wherein the said NSAID is used.

  一种具有必需脂肪酸或必需脂肪酸醇的化合物形式的非甾体抗炎药物，特别是本文第 1 至 9 类所列的非甾体抗炎药物。此外，一种用于治疗包括类风湿性关节炎、骨关节炎及相关疾病；痛经；痴呆症，包括阿尔茨海默氏症；或本文中规定的任何其他炎症或其他病症的药物的制备方法，其中使用了所述非甾体抗炎药。
• MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE
  申请人：Biomarck Pharmaceuticals, Ltd.

  公开号：EP2399599A2

  公开（公告）日：2011-12-28

  Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 23 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided.

  所提供的多肽由少于 24 个氨基酸组成。这些多肽的氨基酸序列选自以下一组：(a)具有 4 至 23 个连续氨基酸的参考序列 PEPTIDE 1 的氨基酸序列；(b)与(a)中定义的序列基本相同的氨基酸序列；以及(c)(a)中定义的氨基酸序列的变体。还提供了一种非肉豆蔻酰化的 MANS 肽。还提供了使用这些肽的各种方法。